Common use of Simplification / Commercialisation Clause in Contracts

Simplification / Commercialisation. The University, in partnership with the Enterprise Agencies, Interface, and the Scottish HEI Sector strives to simplify business access to the knowledge and expertise in Scottish universities. Dundee participates in the UIF Enterprise Support Group (now a sub-group of US RCDG) and in the RCDG Contracts Sub-Group, both of which directly address this outcome. Dundee is recognised as a UK-leading university for commercialisation via commercial licensing and spin-out company formation. In 2021 it placed 6th in the UK in the University Spinout Report 2021 (Gorant), developing 1.5% of the UK’s spinouts with these companies raising £325.7 million over the past two decades, while in 2022 Dundee placed 4th in Beauhurst & Parkwalk “Equity Investment into UK Spin-outs”. These awards recognise outstanding success from companies such as Exscientia Ltd and Amphista Therapeutics Ltd , but also explicitly reference our entrepreneurial ecosystem (see also Outcome 4) We have made great strides over recent years in attracting investment from the global pharmaceutical industry – in 2020/21 our industry research income (HESA) rose to c. £15m. (around 20% of our total research income). We have also been able to invest commercially in Tay Therapeutics Ltd, one of our most high potential spin-outs, demonstrating the University’s commitment to this activity and to economic growth in our region. These successes depend on our continued commitment to deploying UIF in support of the ongoing activities of RIS, our Centre for Entrepreneurship (CfE) and School-based translational units such as the Drug Discovery Unit. We use the RCDG Contract Templates in all our dealings with Scottish-based industry partners and we have been progressively moving towards devolved standardised simple agreements (Non-Disclosure, Material Transfer, etc.) that can be signed off at School level thereby reducing transaction times for company partners. UIF will support our plans for 2022/23 and beyond in this area, including:

Simplification / Commercialisation. The University, in 70. In partnership with the Enterprise Agencies, Agencies and Interface, and the Scottish HEI Sector strives we strive to simplify business access to the our knowledge and expertise in Scottish universitiesexpertise. Dundee participates We participate in the UIF US RCDG Enterprise Support Group (now a sub-group of US RCDGESG) and in the RCDG Contracts Sub-Group, which both of which directly address this outcome. We use RCDG Contract Templates in all dealings with Scottish companies, and have devolved standardised simple agreements (Non-Disclosure, Material Transfer, etc.) to Schools, reducing transaction times for company partners. 71. Dundee is recognised as a UK-leading university UK leader for commercialisation via commercial licensing and spin-out company formation. In 2021 it placed 6th 2023, Dundee was named 1st in the UK in the University Spinout Report 2021 (Gorant), developing 1.5% of the UK’s spinouts with these companies raising £325.7 million over the past two decades, while in 2022 Dundee placed 4th in Beauhurst & Parkwalk “Equity Investment into UK for Spin-outs”out Success by Octopus Ventures in its Entrepreneurial Impact Ranking, to add to several other UK Top 10 placings in independent surveys since 2020. These awards recognise outstanding success from companies such as like Exscientia Ltd and Amphista Therapeutics Ltd Ltd, but also explicitly reference cite our entrepreneurial ecosystem culture (see also Outcome 4) We have made great strides over recent years in attracting investment from the global pharmaceutical industry – in 2020/21 our industry research income (HESA) rose to c. £15m. (around 20% of our total research income). We have also been able to invest commercially in Tay Therapeutics Ltd, one of Our continued success depends on our most high potential spin-outs, demonstrating the University’s commitment to this activity and to economic growth in our region. These successes depend on our continued commitment to deploying deploy UIF in support of the ongoing activities of RIS, our Centre for Entrepreneurship (CfE) and School-based translational units such as assets like the Drug Discovery Unit and the MRC Protein Phosphorylation and Ubiquitylation Unit. 72. In 2023/24 and beyond we will use UIF and UIF-backed staff to: • Make the case, with Glasgow, Edinburgh and Scottish Enterprise, for a pilot Proof of Concept Fund – to increase the number and quality of commercial opportunities from our collective life sciences and biomedical research. This addresses the Innovation Strategy’s “Innovation Investment Programme” goals; • Continue our stage-gated process for commercialisation opportunities, which provides an objective basis for us to invest (modestly) in early-stage technologies and concentrate UIF-backed commercialisation staff resource on the most promising opportunities. 73. The new Research Commercialisation Framework for Scotland will be an important driver of university Knowledge Exchange activity. Dundee already has a strong track record of using its sectoral knowledge strategically to promote greater innovation in the economy, and is committed to promoting economic recovery through Innovation. The Scottish Innovation Strategy’s selection of Health & Life Sciences as one of four Innovation Clusters provides strategic endorsement of one of the main areas where we deploy UIF support to address this outcome. 74. We use opened the RCDG Contract Templates industry-facing Centre for Targeted Protein Degradation (CeTPD) in all 2023, and started building our dealings £40M Life Sciences Innovation Hub with Scottish-based industry partners and we have been progressively moving towards devolved standardised simple agreements (Non-Disclosure, Material Transfer, etc.) that can be signed off at School level thereby reducing transaction times for company partnersTay Cities Deal funding. UIF will support our plans for 2022/23 and beyond in this area, including:We are creating a